'Jurassic World Rebirth' chomps on big $147-million Fourth of July box office weekend
The holiday total for "Jurassic World" in the U.S. and Canada exceeded industry expectations. Universal Pictures' "Jurassic World" reboot was expected to gross $120 million to $130 million during its long opening weekend, according to analyst and studio projections.
The movie unseated Apple's Brad Pitt racing film "F1 The Movie," which landed in second place with $26.1 million domestically, bringing its total to $109.5 million in North America, according to distributor Warner Bros.
"Rebirth's" 2022 predecessor, "Jurassic World: Dominion," debuted with $145 million from its first three days of release and went on to collect $1 billion globally. The new movie carries an estimated production budget of $180 million, not counting marketing costs.
Big-budget creature features have global appeal, as the numbers showed. Opening in 82 countries outside the U.S. and Canada, "Rebirth" grossed $171 million internationally. That included $41.5 million from China, proving that Hollywood movies can still do well in the Middle Kingdom despite the dominance of local production in the populous country.
The global total for "Rebirth's" opening was $318.3 million.
Directed by Gareth Edwards ("The Creator," "Rogue One") and starring Scarlett Johansson and Mahershala Ali, "Rebirth" earned unenthusiastic reviews from critics, notching a 52% approval rating on aggregator Rotten Tomatoes.
The "Jurassic" franchise has seen multiple iterations since Steven Spielberg's landmark 1993 blockbuster "Jurassic Park," based on the popular Michael Crichton science fiction novel, wowed audiences with its combination of practical and computer-generated effects that gave the T. Rex and other killer dinos their stunning realism. That film spawned not only sequels but toys, theme park attractions, animated series and video games.
Although the sequels, starting with Spielberg's own "The Lost World," never achieved the acclaim of the original, they continued to mint money for Universal and Spielberg's production company, Amblin.
Prior to "Rebirth," the "Jurassic" movies had grossed a total of roughly $6 billion worldwide, not adjusting for inflation, according to box office website The Numbers. The first "Jurassic Park" grossed $978 million worldwide, according to Box Office Mojo, which is equal to $1.86 billion in today's dollars.
Read more: Pixar had its worst opening weekend ever with 'Elio.' What happened?
The latest "Jurassic" movie did not get a slot at Imax theaters, since those were taken up by "F1." Next week, the valuable Imax real estate will be taken up by Warner Bros. and DC Studios' "Superman." Films shown on Imax often reap bigger box office numbers, aided in part by the higher ticket prices at those theaters, and because they're viewed as more of a must-see "event."
"Jurassic World" is the first of three big tentpole films arriving this month in theaters. In addition to "Superman," Walt Disney Co. and Marvel Studios' "The Fantastic Four: First Steps" opens in a few weeks.
July has historically been one of the strongest summer months at the box office, putting more pressure on these three films to deliver.
Despite big box office gains in April and May, June saw a string of underperforming films such as Lionsgate's "John Wick" spinoff "Ballerina," Sony Pictures' "Karate Kid: Legends" and Disney and Pixar's original animated effort "Elio."
Theatrical business in June was 25% lower compared to the pre-pandemic average of June 2017, 2018 and 2019, according to David A. Gross's FranchiseRe movie industry newsletter. It was also down 5.3% compared to last June, which saw big hits like Disney and Pixar's "Inside Out 2" and Sony's "Bad Boys: Ride or Die."
"We see this ebb and flow," said Shawn Robbins, founder of the website Box Office Theory. "These next four to five weeks will certainly give us a sense of how to grade the summer overall.'
Sign up for our Wide Shot newsletter to get the latest entertainment business news, analysis and insights.
This story originally appeared in Los Angeles Times.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
35 minutes ago
- CNN
Texas town successfully carried out evacuations, raising questions about Kerr County response
Texas town successfully carried out evacuations, raising questions about Kerr County response Downstream from Kerrville, Texas, the town of Comfort successfully carried out evacuations, raising questions about Kerr County's response. CNN's Pamela Brown reports from Comfort, where a volunteer firefighter says the town's sirens and evacuations were crucial in getting people to safety. 01:34 - Source: CNN Automated CNN Shorts 11 videos Texas town successfully carried out evacuations, raising questions about Kerr County response Downstream from Kerrville, Texas, the town of Comfort successfully carried out evacuations, raising questions about Kerr County's response. CNN's Pamela Brown reports from Comfort, where a volunteer firefighter says the town's sirens and evacuations were crucial in getting people to safety. 01:34 - Source: CNN Netenyahu presents Trump with Nobel Peace Prize nomination letter Israeli Prime Minister Benjamin Netanyahu presented President Donald Trump with a nomination for the Nobel Peace Prize at their dinner at the White House. 01:15 - Source: CNN Immigration enforcement swarms LA park Dozens of federal immigration agents in tactical gear accompanied by members of the California National Guard were deployed Monday to a mostly empty MacArthur Park in Los Angeles Monday morning. It's unclear if anyone was taken into custody during the operation, which sparked outrage among local residents and which Mayor Karen Bass called 'outrageous' and 'an attempt to spread fear.' An Immigration and Customs Enforcement spokesperson told CNN the agency does not comment on ongoing operations. 01:07 - Source: CNN Why did 'Love Island USA's' Cierra Ortega leave the villa Season 7 "Love Island USA" contestant Cierra Ortega left the show due to a "personal situation," according to the dating show. This comes after two social media posts began circulating online that appeared to show Ortega using a racial slur while contemplating cosmetic procedures she wanted to get, according to the Daily Mail. 01:36 - Source: CNN Remembering victims of the Texas floods CNN honors some of the victims of the devastating floods that hit central Texas, leaving the death toll surpassing 100, including at least 27 campers and counselors from Camp Mystic, an all-girls summer camp that sits along the Guadalupe River. 02:01 - Source: CNN Community grapples with how floodings caught so many off guard Kerr County officials and the community are questioning how so many were caught off guard after devastating floods hit central Texas. CNN's Pamela Brown reports from Kerrville. 01:50 - Source: CNN Protesters in Kenya met with water cannons and tear gas Protests in the Kenyan capital of Nairobi erupted on Monday with police seen in video using tear gas and water cannons from armored trucks to disperse crowds. 01:07 - Source: CNN Volunteers line up to look for Texas flood victims Rescue volunteers in Center Point, Texas, are finding the belongings of missing children from the floods. People are also using heavy machinery to help clear debris. CNN's Isabel Rosales spoke with one volunteer who said he's trying to help bring closure to the victims' families. 01:43 - Source: CNN Camp Mystic girls evacuate from flood devastation Videos shared from a Camp Mystic nurse show campers evacuating on a bus while passing devastation from the floods along the Guadalupe River in Texas. 00:49 - Source: CNN Russian minister dies shortly after Putin fired him Former Russian Transport Minister Roman Starovoit died by suicide on Monday, just hours after Russian President Vladimir Putin fired him from the job, officials said. Asked by reporters for the reasons behind Starovoit's dismissal, Kremlin spokesperson Dmitry Peskov denied this was due to a 'lack of trust,' but he did not give any alternative reason. 00:49 - Source: CNN Indonesia's Mount Lewotobi Laki Laki volcano erupts Mount Lewotobi Laki Laki erupted in Indonesia, sending a column of ash as high as 11 miles into the sky. Authorities placed the volcano on the highest alert level last month. 00:43 - Source: CNN
Yahoo
an hour ago
- Yahoo
Richard Simmons' bedazzled tanks sent to auction
Richard Simmons' personal items are set to hit the auction rooms. Bonhams Auction House in Los Angeles has revealed it's auctioning off more than 200 of the late TV fitness instructor's items, including bedazzled tank tops, branded VHS tapes and other memorabilia from his workout empire, TMZ reports. The collection celebrates Simmons' four-decade legacy. Among the star items hitting the block are his signature Sweatin' to the Oldies ensemble, worn during a 2012 Slimmons class; a bedazzled Hummingbird tank top worn at the 2013 MTV VMAs; a custom Pom Pom Ball tank from a 2011 appearance; and more than 100 other glittering tank tops and shorts, each estimated to fetch between $200 and $300 (£150 to £220). Fans can also bid on nostalgic Simmons-branded merchandise, including a portrait of Simmons and his dalmatians by Frank Cummings, estimated at up to $1200 (£880), and the original 'Slimmons' studio sign from his Beverly Hills gym, estimated at up to $700 (£510). The auction runs from 12-24 July, coinciding with what would have been his birthday, and marking a year since he died in 2024. Simmons passed away at the age of 76 on 13 July last year, at his Hollywood Hills home. His death was attributed to complications from falls and heart disease. According to multiple news sources, he was found unresponsive after falling the day before and not wanting to seek medical attention.
Yahoo
an hour ago
- Yahoo
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
SAN DIEGO, July 08, 2025--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe's global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to support CERo's clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chimeric antigen receptor T-cells) and Chimeric Engulfment Receptor T-cells ("CER-T") therapies, which involve engineering a patient's own T-cells to recognize and attack cancer cells, have shown promise in other hematologic malignancies and are now being explored for AML. However, because these therapies are manufactured from patient-derived cells, it's critical to confirm that leukemic blasts are not inadvertently included in the final therapeutic product – underscoring the need for sensitive, validated assays like those offered by Invivoscribe and its global accredited regional laboratories, LabPMM. LabPMM's CAP/CLIA-Validated AML MRD MFC assay, which was designed to quantify residual leukemic cells in patients undergoing treatment, was customized to meet two critical needs in CERo's drug development program: (1) assessing the purity of the manufactured T-cell product by detecting residual AML blasts prior to infusion, and (2) evaluating therapeutic response to CER-1236 during the trial. Kristen Pierce, Ph.D., CERo Chief Development Officer, commented, "Invivoscribe has played an integral role in the execution of this clinical trial. Its technology and expertise have facilitated our advancement into the clinic by helping to ensure the purity of our investigational product, and now we are reaping the benefits of our collaboration as the trial is underway and we seek to assess therapeutic response." This collaborative effort was instrumental in advancing CER-1236, which recently received FDA Orphan Drug Designation for the treatment of AML2. The designation highlights the growing urgency of integrated diagnostic support in the advancement of personalized immunotherapies and reflects Invivoscribe's commitment to driving innovation and standardization across the oncology treatment landscape – now helping bring immunotherapies to patients faster. For more information about LabPMM's flow cytometry and molecular testing services, please visit or contact us at inquiry@ and follow us on LinkedIn. About Invivoscribe Inc. Invivoscribe® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. 1 2 View source version on Contacts inquiry@ Connectez-vous pour accéder à votre portefeuille
